Skip to main content

Table 1 Descriptors for baseline characteristics (average (SD) or count (%), as appropriate) and outcomes of the final sample

From: A parametric model to jointly characterize rate, duration, and severity of exacerbations in episodic diseases

Predictors

Overall (n=1110)

Placebo* (n=323)

75 mg Mepolizumab* (n=317)

100 mg Mepolizumab (n=171)

250 mg Mepolizumab (n=150)

750 mg Mepolizumab (n=149)

Female

668 (60%)

193 (60%)

193 (61%)

102 (60%)

92 (61%)

88 (59%)

Age (years)

49.0 (12.9)

47.7 (13.2)

49.8 (13.0)

50.3 (14.5)

49.1 (11.5)

48.3 (11.1)

Body Mass Index (kg/m\({}^2\))

28.1 (5.9)

28.2 (5.8)

28.0 (5.9)

27.7 (6.0)

28.4 (5.9)

28.7 (5.8)

Duration of asthma (years)

19.3 (14.0)

18.8 (14.3)

19.3 (13.9)

20.2 (12.9)

20.4 (14.0)

18.7 (15.0)

Maintenance daily dose of oral corticosteroids (mg)

4.2 (10.3)

3.5 (8.2)

3.7 (8.9)

3.4 (8.3)

6.4 (17.0)

5.1 (10.3)

Nasal polyps

147 (13%)

47 (14%)

40 (13%)

25 (15%)

22 (15%)

13 (9%)

Percentage of predicted pre-bronchodilator FEV1

60.3 (17.1)

61.1 (16.9)

60.2 (17.5)

59.7 (17.7)

59.3 (16.8)

60.7 (16.0)

FEV1 reversibility (%)

26.4 (21.6)

26.7 (22.4)

26.2 (20.2)

28.9 (25.1)

26.4 (21.0)

23.4 (18.9)

Score on asthma control questionnaire

2.3 (1.1)

2.3 (1.3)

2.2 (1.1)

2.2 (1.2)

2.4 (1.1)

2.2 (1.1)

Blood eosinophil count (\(10^9/\)L)

0.42 (0.40)

0.44 (0.42)

0.40 (0.38)

0.45 (0.43)

0.39 (0.44)

0.36 (0.31)

IgE (U/ml)

447 (1093)

435 (850)

548 (1318)

354 (364)

361 (847)

450 (1593)

Ethnicity (Black/Hispanic)

107 (10%)

31 (10%)

32 (10 %)

16 (9%)

14 (9%)

14 (9%)

History of smoking

247 (22%)

67 (21%)

74 (24%)

41 (24%)

30 (20%)

35 (24%)

Exacerbations requiring admission in year prior to study

3.6 (2.9)

3.7 (3.3)

3.6 (2.7)

3.8 (2.8)

3.4 (2.4)

3.5 (2.9)

Follow-up time (years)

0.78 (0.24)

0.75 (0.24)

0.75 (0.24)

0.61 (0.11)

0.94 (0.21)

0.92 (0.22)

Outcomes

Number of exacerbations (annual rate)

1128 (1.31)

468 (1.94)

251 (1.05)

86 (0.83)

179 (1.27)

144 (1.04)

Duration of exacerbations (days)

14.4 (11.6)

15.0 (12.6)

15.1 (13.3)

12.9 (9.5)

14.1 (8.5)

12.4 (10.0)

Number of severe exacerbations (annual rate)

181 (0.21)

68 (0.28)

39 (0.16)

14 (0.13)

32 (0.23)

28 (0.20)

  1. *Pooled data from both studies FEV1: Forced expiratory volume at one second